Strandberg, Timo E. http://orcid.org/0000-0001-6299-925X
Levinson, Susan L.
DiNubile, Mark J.
Jyväkorpi, Satu
Kivimäki, Mika
Funding for this research was provided by:
bioaegis therapeutics
helsingin ja uudenmaan sairaanhoitopiiri (TYH2020126)
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 24 July 2021
Accepted: 23 January 2022
First Online: 15 February 2022
Declarations
:
: MJD and SLL are employees of BioAegis Therapeutics which is developing rhu-pGSN for clinical use and own stock in the company. TES has had various cooperation (educational, consultative, research with several companies (Amgen, Nestle, Novartis, Nutricia, Orion, Sankyo, Sanofi).
: The follow-up has been approved by the ethical committee of the Department of Medicine of the Helsinki University Hospital.
: Written consent was obtained from participants for the follow-up.
: All authors have approved publication.